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Summary
Objective: Our goal was to identify the magnitude of gastro-protective drugs (GPDs) co-prescription and the proﬁle of patients who received
GPD co-prescription, during nonsteroidal anti-inﬂammatory drugs (NSAIDs) treatment in a ‘‘real life setting’’ of primary care practice.
Methods: A pragmatic prospective 6-month survey of 2197 new takers of nonselective NSAIDs, selected and followed by general practitioners
(GPs) on the bias of their usual standards of care.
Results: Forty-seven percent of our survey population used at least one GPD during the 6-month follow-up. No difference was identiﬁed be-
tween piroxicam, diclofenac, ibuprofen, meloxicam and nimesulid for the GPD co-prescription. Besides the presence of gastro-intestinal (GI)
symptoms, previous use of GPD, previous occurrence of GI disorders and increase in age are the most prominent predictive factors of GPD
use during NSAID treatment. When adjusted for other risk factors, co-prescription of GPD was signiﬁcantly increased in patients aged 55
years and above (odds ratio (OR): 1.29, 95% conﬁdence interval (CI): 1.01e1.64) with no further increase in the co-prescription in older
subjects.
Conclusion: Patients above 55 years with previous history of GI symptoms or GPD use are more likely to beneﬁt from cytoprotective medi-
cations.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
The cost of musculoskeletal conditions is growing with the
aging of the population and the increased utilization of
new medical technologies1. In the USA, according to a
recent comprehensive study of the cost of musculoskeletal
conditions related to 1995, total costs were US$ 214.9
billion, with the medical direct cost and the indirect cost,
respectively, amounting to US$ 88.7 billion and US$
126.2 billion2.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
widely used to treat chronic arthritis pain. They are one of
the most widely prescribed classes of drugs worldwide,
with both prescriptions and over-the-counter formulations
available in most countries3. These agents are a mainstay
of treatment despite their association with clinically relevant
gastric ulcers, perforations and bleedings4. Moreover, non-
selective NSAIDs may induce upper gastro-intestinal (GI)
dyspeptic symptoms, even in the absence of endoscopic
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Received 17 August 2005; revision accepted 3 January 2006.62lesions4,5. The economic impact of these GI side effects
is substantial, resulting in a greater utilization of medical re-
sources. Management of GI toxicity in nonselective NSAID
users may increase the cost of arthritis by as much as
46%6. To address the need for safer NSAIDs, the speciﬁc
cyclooxygenase (COX-2) inhibitors (COXIBs) were devel-
oped and are now approved for use in the USA and EU
for the symptomatic relief of both osteoarthritis (OA) and
rheumatoid arthritis (RA)7,8. Alternatively, studies have
demonstrated that the synthetic prostaglandin analog, miso-
prostol, is effective in preventing the development of endo-
scopically detected gastric and duodenal ulcers in patients
taking long-term NSAIDs therapy9,10. H2-receptor antago-
nists and proton pump inhibitors (PPIs) have been shown
to reduce GI injury related to NSAIDs11,12. In addition, co-
prescription of gastro-protective drugs (GPDs), such as ant-
acids, H2-receptor antagonists or PPIs may occur in more
than 25% of NSAID users13. In most countries, guidelines
exist to minimize the risk of NSAIDs-induced GI toxicity,
recommending that patients at risk should receive either
gastro-protective agents or COXIBs14,15. The deﬁnition of
such ‘‘high risk’’ patients may impact on the decision of
health authorities to reimburse co-prescriptions or even
COXIBs in a speciﬁc subset of the population, hence gener-
ating a signiﬁcant impact on health resources utilization.5
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‘‘high risk’’ patients to ensure that they are properly pro-
tected but also to avoid unnecessary prescriptions of GPD
or COXIBs, generating an inappropriate burden in terms
of health expenditures. While risk factors such as age, con-
comitant use of oral corticosteroids, coumarin, low dose as-
pirin, and history of GI events were repeatedly associated
with an increase in the hazard risk of developing GI side ef-
fects during NSAIDs treatment14,15, there are still some un-
certainties about the exact proﬁle of the individual patient,
who in daily practice, will beneﬁt from a co-prescription
because of NSAIDs. We conducted the present pragmatic
survey to identify the proﬁle of patients receiving GPD co-
prescription, in patients initiating conventional NSAIDs
treatment, for various conditions, in a family practice setting.
Methods
We designed a pragmatic, prospective survey, in which
50 primary care physicians, i.e., Belgian general practi-
tioners (GPs), were asked to recruit 50 consecutive patients
each, for which they felt appropriate, based on their com-
mon practice, to initiate a treatment with nonselective
NSAIDs. When the survey was designed and initiated,
COXIBs were not marketed in Belgium. Patients were
from both genders and aged over 35 years. The exclusion
criteria were previous exposure to investigational COXIBs
at any time, exposure to NSAIDs during the last 3 months.
In order to avoid modifying the risk of GI intolerance to
NSAIDs, we also excluded patients with concomitant intake
of corticosteroids or anticoagulants. The primary objective
of this survey was to evaluate GPD co-prescription in daily
practice. Therefore, GPs were instructed to prescribe
NSAIDs (type, dose and duration) following what they con-
sider to be their usual standard care. In order to speed up
the recruitment, the number of GPs participating in the sur-
vey was increased to 66. Patients were divided into three
diagnostic groups, based on the underlying disease leading
to the NSAIDs prescription: OA, chronic back pain without
OA (BP) and any other medical condition (OMC). At base-
line, we collected information on previous history of GI
disorders and GPD use during the last 3 months. Patients
were seen by their GPs after 3 and 6 months and informa-
tion was collected on NSAIDs intake (compliance and per-
sistence), occurrence of GI adverse reactions and GPD
prescriptions (nature and motivation).
Descriptive statistics were performed on the number of pa-
tients experiencing GI adverse reaction during the 6-month
follow-up or receiving GPD co-prescription. A logistic regres-
sion analysis was performed to estimate odds ratio (OR) of
each variable with its 95% conﬁdence interval (CI) associ-
ated with receipt of NSAID with GPDs vs NSAID alone.
Results
GENERAL DATA
At the end of the preplanned recruitment period, 2197
patients were included. Seventy-two (3.3%) were lost to fol-
low-up and 194 (8.8%) were considered as major protocol
violators (75 were previously exposed to the investigational
use of COXIBs and 119 were below the age limit of 35
years). This left a cohort of 1946 patients for the analyses,
783 (40.2%) in the OA group, 801 (41.2%) in the BP group
and 362 (18.6%) in the OMC group. The mean age (SD)
of the survey population was 62.7 (13.3) years and thefemale/male ratio was 1.88. At inclusion, 743 (38.1%)
patients reported a previous history of one or more GI
disorders. Heartburn was recorded by 614 patients, while
peptic ulcers and previous upper GI surgery were mentioned
by 225 and 30 subjects, respectively. During the 3 months
prior to the survey, 696 (35.8%) patients already received
a GPD, with 267 (13.7%) having been exposed to GPD for
at least 1 month.
At baseline, 1914 (98.4%) patients were instructed to
take one single NSAID. The NSAIDs most frequently
prescribed by the GPs were piroxicam (n¼ 544), diclofenac
(n¼ 313), ibuprofen (n¼ 252), nimesulid (n¼ 231) and
meloxicam (n¼ 182) (Table I). Altogether, these ﬁve most
prescribed NSAIDs totalled 78.2% of the GP’s
prescriptions.
During the ﬁrst 3 months of the survey, a change in
the initial NSAID prescription was recorded in 325 pa-
tients leading 1589 patients to use a single NSAID while
317, 33, 6 and 1 patients used 2, 3, 4 and 5 different
NSAIDs, respectively. During the second 3-month period,
1477 (75.9%) of the patients still took an NSAID. The dis-
tribution of the prescriptions between the different mole-
cules was similar to what was observed during the ﬁrst
period.
During the 6-month survey, 1257 (64.6%) patients expe-
rienced at least one GI symptom, the most frequent being
epigastric pain, heartburn, and nausea (Table II). Overall,
915 (47%) patients who participated in the trial received
at least one GPD (Fig. 1). Between the initiation of the
NSAID treatment and the ﬁrst follow-up visit (month 3),
762 patients (39.2%) took at least one GPD with 85
patients (11.1%) being prescribed more than one GPD.
Table III summarizes the nature, mean daily dose and du-
ration of treatment for the ﬁve most commonly prescribed
GPDs during the ﬁrst 3 months of the survey. Five hun-
dred and thirty-six of these patients (70%) did not use
a GPD during the 3-month period prior to the trial or
used it for less than 1 month. The pattern of GPD use dur-
ing the second period of the survey was similar with 775
patients (39.8%) and 82 patients (10.6%) being prescribed
at least one and more than one GPD, respectively. When
comparing the patients who took an NSAID during the
second period of follow-up to those who did not pursue
the treatment after the month 3 visit, there is a highly sig-
niﬁcant difference between the prevalences of GPD pre-
scription (P< 0.05) (45.1% in NSAID users vs 23.2% in
NSAID nonusers) (Fig. 1).
When GPs were questioned on their motivation for GPD
prescription, they reported ‘‘prevention or treatment of
NSAIDs GI toxicity’’ in 45.9% (ﬁrst 3 months) and 42.2%
(last 3 months) of the total amount of GPD prescriptions.
No difference was recorded between the ﬁve most com-
monly prescribed NSAIDs for the rate of GPDs prescribed
for prevention or treatment of NSAIDs GI toxicity.
Table I
Duration of intake for the five most commonly prescribed NSAIDs
during the first study period (inclusion to month 3)
NSAIDs Less than
1 week (n)
1e4 weeks
(n)
1e3 months
(n)
Piroxicam 319 72 180
Diclofenac 41 179 115
Ibuprofen 54 161 88
Nimesulid 27 149 69
Meloxicam 12 98 87
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Patient age was signiﬁcantly associated with GPD co-
prescription. Patients above 46 years were more likely to re-
ceive a GPD than younger patients (OR: 1.22, 95% CI:
1.04e1.43). Increasing the age thresholds up to 65 years
did not signiﬁcantly modify the magnitude of the relationship
between age and the use of GPD (Table IV). A previous his-
tory of GPD use, the presence of GI symptoms and a previ-
ous history of GI symptoms were also signiﬁcant, positive
and independent factors for GPD co-prescription during
NSAIDs treatment, for the overall survey. When standardiz-
ing for previous use of GPD and history of GI symptoms, the
OR for GPD use as a function of age became statistically
signiﬁcantly increased at the age of 55 years (OR: 1.29,
95% CI: 1.01e1.64) (patients above 55 years compared
to patients below 55 years) and did not signiﬁcantly in-
crease for higher age limits (Table IV).
The duration of NSAID treatment was negatively associ-
ated with the use of GPD during the ﬁrst 3 months of the sur-
vey. Patients who used NSAIDs for less than 1 month were
more likely to receive GPD. Gender, diagnosis (OA, BP or
OMC) or the number of NSAIDs taken during the survey
did not signiﬁcantly inﬂuence the prescription of GPD.
Discussion
The objective of this survey was to identify the proﬁle of
patients receiving GPD co-prescription, during NSAIDs
Table II
Incidence of the GI symptoms experienced during the first study pe-
riod (inclusion to month 3) and during the second study period
(months 3 to month 6)
GI symptoms % of patients
experiencing GI
symptoms during
the ﬁrst study
period
% of patients
experiencing GI
symptoms during
the second study
period
Epigastric pain 83 73
Heartburn 47.3 42.8
Nausea 29.7 26.3
Constipation 19.8 19.5
Vomiting 5.8 4.1
Fig. 1. Prevalence of GPD use in the overall cohort during the 6-
month study, between inclusion and month 3, between month 3
and month 6 in the overall cohort and, during the period from month
3 to month 6 in NSAID users and nonusers.treatment in a ‘‘real life setting’’ of primary care practice.
GI adverse events in patients taking NSAIDs contribute sig-
niﬁcantly to the increase in resources utilization and overall
costs of the treatment, while also decreasing patient’s qual-
ity of life3. In the UK, the cost of co-prescription of GPDs ac-
counted for 85% of the total annual cost (hospitalization and
co-prescriptions) to the National Health Service for the treat-
ment of GI adverse events in patients taking NSAIDs16. In
a retrospectively collected random cohort of US citizens,
over 65 years old, the risk of GPD use for a nonselective
NSAID user was two-fold increased compared to a subject
non using NSAIDs17.
Our survey population includes a large cohort of subjects
suffering from OA or chronic back pain, two conditions for
which NSAIDs prescription is considered as a common
practice14,15 and also two of the most frequent conditions
why patients consult a family practitioner18,19. The ﬁve
most frequently prescribed NSAIDs represented 78.2% of
the total amount of prescriptions, in accordance with the na-
tional prescription pattern of NSAIDs for GPs and also in
agreement with previous publications performed in similar
settings20. Of our patients 16.6% switched between differ-
ent NSAIDs during the ﬁrst 3 months of the survey, in accor-
dance with an analysis performed in the patients from the
UK MediPlus database, reporting a rate of 0.39 switch/pa-
tient/year in new takers of NSAIDs20. In this particular study,
switching was associated with a 24% increased probability
of GPD prescription in new takers. In the present trial, the
number of different NSAIDs used by the patient during the
survey does not signiﬁcantly correlate to the use of GPD.
As in our survey, dyspepsia is the most common side effect
associated with NSAID use and depending on the deﬁnition
of dyspepsia used in the studies, its prevalence in NSAID
users varies between 5% and 50%, not too far from the
64.7% prevalence for all GI symptoms, reported in this trial3.
Common side effects such as nausea and dyspepsia corre-
late poorly with serious adverse GI events5,14 but they are,
Table III
Mean daily dose (mg/day) and duration of treatment for the five
most commonly prescribed GPDs during the first study period (in-
clusion to month 3)
GPD n Mean
daily
dose
95% CI <1
month
(n)
>1
month
(n)
Ranitidine 228 251.1 241.2e261.0 113 105
Antacids 149 691.7 594.7e788.7 133 16
Omeprazole 125 17.1 15.9e18.3 25 106
Domperidone 114 23.6 21.4e25.7 99 15
Lansoprazole 61 20.2 18.4e21.9 12 49
Table IV
Association between age and the use of GPD. Crude OR with cor-
responding 95% CI, unadjusted, and OR with corresponding 95%
CI adjusted for previous history of GI symptoms and previous use
of GPDs
Variable
(years)
OR crude 95% CI OR adjusted 95% CI
>45 1.18 0.99e1.39 1.24 0.88e1.76
>46 1.22 1.04e1.43 1.32 0.94e1.84
>50 1.22 1.06e1.38 1.27 0.96e1.67
>55 1.20 1.06e1.30 1.29 1.01e1.64
>60 1.18 1.07e1.30 1.30 1.04e1.63
>65 1.18 1.07e1.18 1.32 1.06e1.65
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tion, as shown in the present survey and others21. Overall,
47% of our survey population used at least one GPD during
the 6-month follow-up with a prescription proﬁle in accor-
dance with the expectations, for Belgium GPs. However,
the overall prescription rate for GPD, in our study, is rela-
tively high compared to those previously reported. In fact,
prior studies have shown that a minority of NSAID users re-
ceive GI prophylaxis and that strategies to reduce the risk of
GI bleeding may be underutilized or inappropriate. The high
rate of GPD co-prescription reported in our study may have
many explanations. First, because of differences in patient
population and study design, studies cannot easily be com-
pared with ours. Second, it cannot be excluded that, in the
present study, GP prescription habits were inﬂuenced by
the aim of the study, which was clearly presented to the
GPs, and by the nature of items included in the question-
naire. In particular, the weight given to items relative to
the prescription of GPDs may have drawn their attention
to this adjuvant treatment and induced prescription rates
higher than those really found in normal practice. It is also
possible that the feeling of being under observation induced
a more cautious behavior among GPs. Furthermore, self-
reported physician practice may not accurately reﬂect actual
practice, introducing the potential for biasing self-reports to-
ward higher quality levels22. Third, GPs who agreed to ac-
tively participate in our study may not represent a random
sample of the Belgian GPs. Consequently, we cannot ex-
clude the existence of differences in some characteristics,
such as activity level, year of graduation, practice area or
regular attendance at postgraduate medical training ses-
sions. All these factors may have inﬂuenced GP prescrip-
tion habits and may therefore affect the generalization of
the results. However, although the prescribing pattern of
these GPs may not reﬂect those of all Belgian primary
care physicians, the prescription pattern of NSAIDs, in our
study, was, as previously mentioned, in accordance with
the national prescription pattern of NSAIDs. In addition,
the GPD co-prescriptions seem to be adapted to the
potential risk of occurrence of GI side effects and to be in
agreement with prescribing guidelines. Last, the 6-month
follow-up and so the duration of exposure to NSAIDs may
also have inﬂuenced the pattern of prescription of GPs. In
fact, in our survey, the duration of exposure to NSAIDs
was negatively associated to the use of GPD but only dur-
ing the ﬁrst 3 months of the survey; the rate of GPD co-
prescription was signiﬁcantly higher among patients who
used NSAIDs for less than 1 month. This result reﬂects
the concerns of GPs about early GI toxicity with the use
of NSAIDs and the high level of awareness of GPs about
these side effects. Conﬂicting results have been reported
for the relationship of the risk of GI events to the duration
of exposure to NSAIDs15. As in the present trial, epidemio-
logic studies have reported that the rates of GI discomforts
are not constant over time, with the highest risk occurring in
the ﬁrst months of NSAIDs use15,23e25. Conversely, the risk
of serious GI events, which were not assessed in our survey
due to our limited sample size and duration of exposure,
has been shown to be constant over time7,24,26.
Over the whole period of the survey, we did not report any
signiﬁcant difference between the ﬁve most frequently
prescribed NSAIDs, for the percentage of patients being
prescribed a GPD for prevention or treatment of NSAIDs-
related GI side effects. Conﬂicting results exist in the litera-
ture, between epidemiologic or randomized controlled trials
assessing the gastrotoxicity of various NSAIDs and their re-
lation to the co-prescription of GPDs13,15,25e28. From ourpragmatic results, obtained in a real life setting, we cannot
identify any difference between piroxicam, diclofenac, ibu-
profen, meloxicam and nimesulid for the risk to induce
a GPD co-prescription. Similar results were obtained in
a cross-sectional, GP-based survey, performed in France,
on patients aged over 18 years29. These results show
that, besides the presence of GI symptoms, previous use
of GPD, previous occurrence of GI disorders and increase
in age are the three most prominent factors of GPD use dur-
ing NSAID treatment. A history of GI disorder, during the
previous year has been associated to a signiﬁcant increase
in the rate of dyspepsia, abdominal pain and peptic ulcers,
occurring during NSAIDs use. These conditions were also
associated, as observed in the present trial, to a two- to
three-fold increase in co-prescription of GPDs in general
practice in England21. In the French general practice-based
survey, age and previous history of moderate to severe di-
gestive disorders were independent determinants associ-
ated with the co-prescription of a cytoprotective agent with
NSAIDs29. While cytoprotective drugs were not available
in Belgium at the time of our survey, these French results
are in accordance with our results regarding other GPDs.
As in our trial, prior GPD use was the strongest predictor
of subsequent concomitant GPD/NSAID use in a large
US-based prescription database, including all patients
with at least one NSAID prescription dispensed during an
18-month period30.
Our results suggest that younger individuals, from the
age of 55 years, may be at signiﬁcantly higher need for
GPD co-prescriptions. We are in agreement with the results
of a retrospective cohort study using an Italian regional
health service database comprising all subjects receiving
NSAIDs during 2 years which reported that the iatrogenic
costs of NSAIDs were generated by 12.4% of the popula-
tion, 77% of whom had a positive history of GI disorders
and 82% were older than 50 years31.
We choose to collect and to present our data in incre-
ments of 3 months over the 6-month time period exposure
for many reasons. First, as mentioned above, a number of
epidemiologic studies have suggested that the risk of GI
complications is higher at the onset of long-term NSAID
treatment. In order to take into account the possible impact
of duration of exposition to NSAIDs on the occurrence of
early GI side effects and consequently on the GPD co-
prescription, we planned to collect data at 3 and 6 months
after initiation of treatment. Second, in a perspective of ra-
tionalization of health resources, it is important to know
the moment which the prescription is initiated and the
reasons why GPs prescribe a treatment. In a societal per-
spective, the impact at 3 months on the pattern of GPD
co-prescription may be an important information in the con-
text of reimbursement policies.
We acknowledge a certain number of limitations in our
survey. The ‘‘real life’’ design requested to limit, as much
as possible, any external intervention upon the manage-
ment of patients performed by the GP. Subsequently, the
patterns of prescription, follow-up and data collection are
far from the standards usually obtained in randomized con-
trolled trials. As mentioned above, prescribing practices
may be different outside of the study context. We also delib-
erately excluded patients with concomitant intake of cortico-
steroids or anticoagulants, medications that are known to
substantially modify the risk of GI intolerance to NSAIDs15.
COXIBs were not commercially available in Belgium for the
most part of our survey. They got reimbursed during the
very last stage of our recruitment period. We thus cannot to-
tally exclude that some of the latest patients recruited in our
629Osteoarthritis and Cartilage Vol. 14, No. 7trial and treated with conventional NSAIDs might be better
cases than the average NSAIDs users. Notwithstanding,
the number of patients potentially affected remains highly
marginal and this bias could only have decreased the
need for GPD co-prescription, since the most severe cases
would, at that time, have been directed to COXIBs. Eventu-
ally, we did not gather any information on the presence of
Helicobacter pylori for which conﬂicting results have been
reported regarding a possible synergistic effect with
NSAIDs to generate GI side effects14,15.
In conclusion, our 6-month prospective survey, performed
in a real life setting of primary care physicians suggests that
a large number of patients initiating a treatment with NSAIDs
experience GI disturbances leading to a 47% rate of GPD
co-prescription. No signiﬁcant differences in the need for
GPDs were observed between the ﬁve most frequently pre-
scribed NSAIDs. Major determinants of the need for GPDs
are a previous history of GPD use, current or past history
of GI symptoms and increasing age. When we adjusted for
a previous history of GI discomfort and previous GPD use,
co-prescription of GPD was signiﬁcantly increased, from
the age of 55 years, with no further increase in the rate of
co-prescription in older subjects.
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